“Phase 3 Trial Demonstrates Superior Patient Treatment Convenience of MC2-01 Calcipotriene Plus Betamethasone Dipropionate Cream Compared to Current Topical Suspension”. 2020. SKIN The Journal of Cutaneous Medicine 4 (5): s62. https://doi.org/10.25251/skin.4.supp.61.